Elekta (OTCMKTS:EKTAY) Trading Down 1% – What’s Next?

Elekta AB (OTCMKTS:EKTAY) fell 1% on Thursday . The stock traded as low as $4.91 and last traded at $4.91. 2,585 shares were traded during trading, a decline of 67% from the average session volume of 7,817 shares. The stock had previously closed at $4.96.

Analysts Set New Price Targets

Separately, Danske cut Elekta to a “hold” rating in a research report on Tuesday, June 3rd.

Elekta Stock Up 0.9%

The company has a current ratio of 1.09, a quick ratio of 0.86 and a debt-to-equity ratio of 0.70. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of 99.12 and a beta of 1.22. The firm has a 50-day moving average of $5.10 and a two-hundred day moving average of $5.40.

Elekta (OTCMKTS:EKTAY) last posted its quarterly earnings data on Wednesday, May 28th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.02). Elekta had a return on equity of 11.55% and a net margin of 1.15%. The business had revenue of $503.22 million for the quarter, compared to analyst estimates of $507.19 million. As a group, sell-side analysts predict that Elekta AB will post 0.36 earnings per share for the current fiscal year.

Elekta Company Profile

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.